WHO-Recommended Periodic Presumptive Treatment versus Doxycycline Post-Exposure Prophylaxis for STI Control among Cisgender Men Who Have Sex with Men in Kenya

ational Institute of Allergy and Infectious Diseases0 个研究点目标入组 2,900 人开始时间: 2024年7月9日最近更新: 2024年8月19日

试验速览

暂无简介。

•18-29 years old
•Assigned male sex at birth
•Identifies as male (cis-gender)
•Reports condomless anal intercourse with a man in the past 6 months
•Reports multiple male sex partners OR a male sex partner with a syndromic (urethritis, proctitis, or genital ulcer disease) or laboratory-diagnosed sexually transmitted infection in the past 6 months
•Willing and able to provide written informed consent and participate in all study procedures
•Planning to remain in the study area for 18 months

•Unable to understand the study purpose and procedures
•Allergy to cephalosporin (cefixime), macrolide (erythromycin or azithromycin), or tetracycline (doxycycline) class antibiotics
•Recent use of prolonged antibiotics (=14-day course in the month before enrolment)
•Use of medications that impact cefixime, azithromycin, or doxycycline metabolism (check versus list in screening SOP)

发起方

ational Institute of Allergy and Infectious Diseases